Who
Andrew D. Goldberg
Director
Company insider
Files Form 4 as: Director, Tarsus Pharmaceuticals; CEO and President, Achieve Life Sciences.
In numbers
- Trades disclosed
- 33
- Buys
- 1
- Sells
- 0
- Bought
- $19K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 15 Jun 2021
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,837 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,417 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,954 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —2,954 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —1,800,965 at $0.00 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —3,601,929 at $0.00 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,706,270 at $0.00 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —1,800,965 at $0.00 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —3,601,929 at $0.00 | filing |
| 18 Apr 2026filed 21 Apr 2026 | ACHV Achieve Life Sciencesoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,706,270 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,350 at $0.00 | filing |
| 13 Jun 2025filed 16 Jun 2025 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,350 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,540 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,954 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | TARS Tarsus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,000 at $0.00 | filing |
| 7 Mar 2025filed 11 Mar 2025 | TARS Tarsus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $90K7,000 at $12.89 | filing |
News
No headline names them, or the companies they trade most, lately.